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Animal models of infective endocarditis (IE) induced by high-grade bacteremia revealed the pathogenic roles of Staphylococcus
aureus surface adhesins and platelet aggregation in the infection process. In humans, however, S. aureus IE possibly occurs
through repeated bouts of low-grade bacteremia from a colonized site or intravenous device. Here we used a rat model of IE in-
duced by continuous low-grade bacteremia to explore further the contributions of S. aureus virulence factors to the initiation of
IE. Rats with aortic vegetations were inoculated by continuous intravenous infusion (0.0017 ml/min over 10 h) with 106 CFU of
Lactococcus lactis pIL253 or a recombinant L. lactis strain expressing an individual S. aureus surface protein (ClfA, FnbpA,
BCD, or SdrE) conferring a particular adhesive or platelet aggregation property. Vegetation infection was assessed 24 h later.
Plasma was collected at 0, 2, and 6 h postinoculation to quantify the expression of tumor necrosis factor (TNF), interleukin 1
(IL-1), IL-1, IL-6, and IL-10. The percentage of vegetation infection relative to that with strain pIL253 (11%) increased when
binding to fibrinogen was conferred on L. lactis (ClfA strain) (52%; P 0.007) and increased further with adhesion to fibronec-
tin (FnbpA strain) (75%; P< 0.001). Expression of fibronectin binding alone was not sufficient to induce IE (BCD strain) (10%
of infection). Platelet aggregation increased the risk of vegetation infection (SdrE strain) (30%). Conferring adhesion to fibrino-
gen and fibronectin favored IL-1 and IL-6 production. Our results, with a model of IE induced by low-grade bacteremia, resem-
bling human disease, extend the essential role of fibrinogen binding in the initiation of S. aureus IE. Triggering of platelet aggre-
gation or an inflammatory response may contribute to or promote the development of IE.
Staphylococcus aureus is currently the major etiological agent ofinfective endocarditis (IE) (1). The pathogenesis of S. aureus-
induced IE has been shown to involve a series of complex interac-
tions between a variety of bacterial surface adhesins, proteins of
the extracellularmatrix, platelets, and inflammation. These events
lead to the formation of vegetations at the injured cardiac valve,
followed by bacterial embedment in the nascent vegetation and
proliferation of vegetations (1, 2).
Major S. aureus cell wall-associated adhesins include the fibrin-
ogen-binding proteins clumping factor A and B (ClfA and ClfB)
and fibronectin-binding proteins A and B (FnbpA and FnbpB)
(3). These surface proteins bind to fibrinogen and/or fibronectin
and trigger platelet activation and aggregation through interac-
tion with specific platelet membrane receptors (4–9). Additional
important members of cell wall-anchored proteins are the Sdr
proteins (for serine-aspartate repeats), which include SdrC, SdrD,
and SdrE (10). Among them, SdrE has been identified previously
as unable to interact with both fibrinogen and fibronectin but
capable of inducing platelet aggregation (11).
Support for the comprehension of the pathogenesis of S. au-
reus IE comes predominantly from studies in animal models. For
instance, it has been demonstrated that the incidence of experi-
mental IE was reduced in rats inoculated with ClfA-negative or
FnbpA-negative S. aureus strains (12, 13). Moreover, it has been
shown that after individual expression of ClfA and FnbpA in the
nonpathogenic bacterium Lactococcus lactis, fibrinogen binding
was pivotal in promoting IE, while fibronectin binding was nec-
essary for persistent valve colonization and endothelial invasion
(14, 15). FnbpA has also been demonstrated to lead to adhesion
and internalization of S. aureus into endothelial cells in vitro and
to contribute to inflammation by the production of proinflamma-
tory cytokines, such as interleukin 1 (IL-1) and IL-6 (16–20).
SdrE also contributes to valve infection, but to a lesser extent than
ClfA or FnbpA (21).
Amajor limitation of these studies on S. aureus pathogenesis is
that they were performed in IE models where infection was in-
duced by bolus inoculation of large numbers of bacteria (between
105 and 107 CFU). Such inocula resulted in massive, high-grade
bacteremia, which is incomparably greater than the spontaneous
or procedure-induced bacteremia occurring in humans. Indeed,
in humans, S. aureus IE possibly follows cumulative low-grade
bacteremia, which could result from a colonized site (22), from
injection of impure material in cases of intravenous (i.v.) drug
abuse, or from more or less prolonged low-grade staphylococcal
discharges from an infected intravascular device, rather than from
transient high-grade bacteremia (23).Thus, the question is
whether the results obtained with the bolus model are fully rele-
vant to human IE.
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We have recently established a new model of experimental IE
in rats where valve infection was induced by continuous injection
of bacteria at a very slow pace (24). The results showed that low-
grade continuous infusion (over at least 10 h) was as infective as
traditional high-grade bolus injection (24). This newly developed
model of IE is expected to be closer to the human situation than
the bolus inoculation model.
In the present work, we used the low-grade continuous-infusion
model and recombinant L. lactis strains expressing individual S. au-
reus surface proteins to further investigate the roles of adhesion to
fibrinogen, adhesion to fibronectin, and platelet aggregation in the
initiation of IE.
(Parts of the present study were presented at the 50th Inter-
science Conference on Antimicrobial Agents and Chemotherapy
[ICAAC], Boston, MA, 12 to 15 September 2010, and to the 22th
European Congress of Clinical Microbiology and Infectious Dis-
eases [ECCMID], London, United Kingdom, 31 March to 3 April
2012.)
MATERIALS AND METHODS
Bacterial strains and growth conditions. The L. lactis strains used in this
study are well-described recombinant strains of the nonvirulent Lactococ-
cus lactis subsp. cremoris strain 1363 expressing individual S. aureus pro-
teins in their surface, i.e., the L. lactis ClfA, L. lactis FnbpA, L. lactis BCD
(expressing a truncated form of FnbpA with only the fibronectin-binding
domain [BCD], lacking the fibrinogen-binding domain [A]), and L. lactis
SdrE strains (14, 15, 21). These strains possess fibrinogen and/or fibronec-
tin adhesion and platelet aggregation properties, individually or in com-
bination, allowing the investigation of the specific role of each factor in the
initiation of IE. L. lactis pIL253, expressing only the erythromycin resis-
tance determinant and lacking adhesive and aggregation properties, was
used as a controlmutant strain. All lactococci were grown at 30°Cwithout
shaking inM17 brothmedium (Difco; BectonDickinson, Sparks,MD) or
on M17 agar plates supplemented with 0.5% glucose and 5 g/ml eryth-
romycin. Bacterial stocks were kept at 80°C in liquid medium supple-
mented with 20% (vol/vol) glycerol.
Bacterial adhesion to solid-phase fibrinogen or fibronectin. The
ability of L. lactis strains to bind to surface-adsorbed fibrinogen (Sigma,
Buchs, Switzerland) or fibronectin (Sigma) was determined by using a
96-well plate assay, and the adherence score was calculated as described
previously (25).
Platelet preparation. Whole blood was drawn from healthy donors,
who had not taken nonsteroidal anti-inflammatory drugs during the pre-
vious 10 days, into citrate-containing tubes. Platelet-rich plasma (PRP)
was prepared by centrifugation of blood at room temperature at 150 g
for 10 min. The blood that remained after the removal of PRP was centri-
fuged at 630 g for 10min to obtain platelet-poor plasma (PPP). The PPP
was used to adjust the PRP to a final concentration of 2 1011 platelets/
ml, as used in routine clinical hematology laboratories. Because PRP al-
ready contains physiological concentrations of fibrinogen but not of fi-
bronectin, the PRP suspension was supplemented with fibronectin to a
final concentration of 50 g/ml (5).
Quantification of aggregation.The ability of L. lactis strains to induce
platelet aggregation in vitro was evaluated using two distinct methods: (i)
aggregometry, as used in routine clinical hematology laboratories, and (ii)
fluorescence microscopy under conditions of high shear stress, to closely
mimic the situation in arteries.
Aggregometry was performed as described previously (26). Twenty
microliters of L. lactis (final concentration, 1  108 CFU/ml in Tyrode’s
buffer) was added to 180 l of PRP in siliconized flat-bottom cuvettes.
Platelet aggregation wasmonitored by an increase in light transmission at
37°C with stirring at 120 rpm using a LABiTec Apact 4004 aggregometer
(LABiTec GmbH, Ahrensburg, Germany). The light transmission of PRP
without added bacteria and the light transmission of PPP were defined as
0% and 100% light transmission, respectively. Platelets were also tested
with 10 l ADP, used as a positive control. Aggregation was recorded for
40 min. Strains were compared with regard to the interval between the
addition of organisms to the PRP suspension and the onset of the aggre-
gation response (lag time) and the number of platelets (expressed as a
percentage) that were aggregated in the presence of bacteria (maximal
aggregation). Three independent assays were performed.
Platelet aggregation under high shear rates (800 s1) was analyzed by
fluorescence microscopy, by a modification of a previously described
method (27), in -Slide VI0.4 flow chambers (ibidi GmbH, Martinsried,
Germany). Because previous studies have shown that L. lactis failed to
adhere to the plastic surface of the flow chamber, probably due to the
surface charge, chambers were prepared to generate appropriate charges
and to ensure the binding of bacteria, as described previously (27). Briefly,
flow chambers were submersed in 100l of 1% Triton X-100 (Sigma) for
30 min and were washed twice in distilled H2O. The chambers were then
sterilized using 95% ethanol and were allowed to air dry. In order to
produce a covalently bound amino group on the plastic surface, the slides
were covered with a fresh 2% solution of 3-aminopropyltriethoxysilane
(Sigma) in dry acetone for 5 s, rinsed twice in distilled H2O, and dried
overnight at 42°C. A 100 l solution of L. lactis (108 cells in Tyrode’s
buffer) was applied to the chambers and was allowed to adhere for 18 h at
4°C. The flow chambers were then washed once with saline to remove any
unbound bacteria. The interaction of platelets with bound L. lactis was
studied by infusing PRP, labeled with 0.5 ng/ml of DiOC6 (Sigma), at a
shear rate of 800 s1, for 15 min. To assess nonspecific platelet adhesion,
a suspension of PRP was perfused over chambers containing no bacteria.
The flow rate was created using a programmable infusion pump (Pump
44; Harvard Apparatus, Inc., South Natick, MA), and platelet aggregation
was visualized under a Leica DMI400 B automated inverted microscope
(Leica AG, Nidau, Switzerland). Pictures were taken every 5 s up to 300 s
using a Leica AF6000 camera. Platelet aggregation was analyzed using
ImageJ software (Wayne Rasband, National Institutes of Health, Be-
thesda, MD), by considering the percentage of surface coverage to be the
percentage of platelet aggregation.
Studies of the inhibition of platelet aggregation. To analyze the ef-
fects of aggregation inhibitors, platelets were incubated for 10min prior to
the addition of bacteria with aspirin (50 g/ml), an inhibitor of cycloox-
ygenase 1, or with abciximab (10 g/ml), an antagonist of the glycopro-
tein IIb/IIIa (GPIIb/IIIa) platelet receptor for fibrinogen and fibronectin
(5).
Animal model of endocarditis. All animal experiments were carried
out according to Swiss regulations (authorization 879.8). Catheter-in-
duced aortic vegetations were produced in female Wistar rats, and an
intravenous (i.v.) line, connected to a programmable infusion pump
(Pump 44; Harvard Apparatus), was inserted into the jugular vein to
deliver the inocula, as described previously (28, 29).
Bacteria were grown overnight, recovered by centrifugation, washed,
and adjusted to the desired inoculum size (106 CFU) in saline. The inoc-
ulum size was confirmed by colony counts on blood agar plates. This
inoculumwas chosen because it permitted a clear differentiation between
infection with recombinant L. lactis and infection with the nonvirulent L.
lactis strain pIL253 in previous studies (14, 15, 21). Animals were inocu-
lated 24 h after catheterization, via the infusion pump, by either of two
distinct protocols. In protocol 1, animals received an i.v. bolus (1 ml in 1
min) of 106 CFU. In protocol 2, animals received the same total absolute
numbers of bacteria as in protocol 1, but the bacteria were delivered pro-
gressively at a pace of 0.0017 ml/min over 10 h. During this period, no
growth of the original inoculum used for challenge was observed, as
checked in preliminary experiments.
To evaluate bacteremia, 1 ml of blood was drawn into heparin-con-
taining tubes from a random subset of 3 to 5 animals per group. Samples
were taken just before inoculation and either 1 min and 2 h (bolus injec-
tion) or 2 h and 6 h (continuous infusion) after the start of inoculation
(24). Serial dilutions of blood were spread onto M17 agar plates, and
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colonies were enumerated after incubation for 48 h at 30°C. The sensitiv-
ity of the assay was 1 CFU/ml of blood.
Rats were sacrificed 24 h after the end of inoculation. Quantitative
valve cultures were performed as described previously (24, 30). This
method permitted the detection of 2 log10 CFU/g of vegetation.
Determination of cytokines in plasma. Levels of tumor necrosis fac-
tor (TNF), IL-1, IL-1, IL-6, and IL-10 were measured in the plasma of
animals inoculated with either L. lactis pIL253, the L. lactis ClfA strain, or
the L. lactis FnbpA strain by using the Bio-Plex Rat Cytokine assay (Bio-
Rad, Hercules, CA) according to the manufacturer’s indications. Blood
was collected into heparinized tubes before inoculation and 2 h and 6 h
postinoculation and was centrifuged at 10,000 rpm for 5 min. Plasma was
preserved at 80°C until analysis. The lower detection limit for TNF,
IL-1, IL-1, IL-6, and IL-10 was 1 pg/ml.
Statistical analysis. The adherence scores of the different bacteria and
their abilities to trigger platelet aggregation were compared by the un-
paired t test. Plasma cytokine values were compared by one-way analysis
of variance (ANOVA) with Tukey’s correction for multiple comparisons.
The percentages of vegetation infection in each inoculation group were
analyzed descriptively by Fisher’s exact test. We complemented the de-
scriptive approach with a logistic regression model in order to determine
the role of fibrinogen adherence, fibronectin adherence, and platelet ag-
gregation in the risk of infection. Note that in the presence of these three
confounding factors, a full factorial design would require 23 (i.e., 8)
groups per inoculation method, whereas only 5 groups were examined in
this study. As a consequence, some confounding remains, and it is not
possible to identify all themain effects and interaction terms in themodel.
For instance, since all strains featuring fibrinogen adherence (Fg) also
induced platelet aggregation (PlAgg), it is not possible to identify themain
effect of Fg on the risk of infection (instead of Fg alone, we use the term
Fg PlAgg). Therefore, we considered Fg PlAgg, PlAgg, and fibronec-
tin adherence (Fn) as themaineffects in the logisticmodel and looked for the
presence of an interaction between FgPlAgg and Fn [(FgPlAgg) Fn].
Data were either analyzed separately or pooled in a single data set. In the
modeling of pooled data, a bolus term interacting with all the terms men-
tioned abovewas also included inorder to capture anydifferencebetween the
two inoculationmethods. All statistical analyses were conducted with R soft-
ware for statistical computing (31).
RESULTS
Bacterial adhesion to immobilized fibrinogen and fibronectin.
L. lactis pIL253 showed no binding to fibrinogen (adherence
score, 0.01  0.01) or to fibronectin (adherence score, 0.27 
0.02). The adherence scores for the recombinant strains indicated
that, compared to strain pIL253, L. lactis expressing ClfA was able
to bind to fibrinogen (13.55 0.79;P 0.001);L. lactis expressing
full-length FnbpA was able to bind to both fibrinogen and fi-
bronectin (8.37  3.91 and 7.60  2.73, respectively; P  0.02);
and the L. lactis BCD strain, expressing the fibrinogen-truncated
form of FnbpA, failed to bind to fibrinogen (0.15  0.07) but
maintained the adhesion to fibronectin (3.07 0.26; P 0.001).
L. lactis expressing SdrE failed to bind to either fibrinogen (0.03
0.03) or fibronectin (0.15  0.04). These results were consistent
with those described previously and confirmed the phenotype of
each isolate (11, 14, 15).
Effects of S. aureus surface proteins expressed in L. lactis on
platelet aggregation.Theplatelet aggregation resultsmeasured by
light transmission are shown in Fig. 1. No platelet aggregation
induced by L. lactis pIL253 was observed. The expression of ClfA
or FnbpA in L. lactis led to a significantly shorter platelet aggrega-
tion time (lag times, 2.66 0.13 and 3.62 0.36min, respectively
[P 0.05]) (Fig. 1A). L. lactis expressing SdrE stimulated platelet
aggregation with a longer lag time (7.33 0.82 min) than that for
L. lactis expressing ClfA or FnbpA, a result similar to that pub-
lished previously (11). In contrast, the L. lactis BCD strain, ex-
pressing the truncated form of FnbpA lacking the fibrinogen-
binding domain, did not promote platelet activation within 40
min after the addition of the bacterial inoculum to PRP. Maximal
aggregation assessed after 40 min (Fig. 1B) showed a pattern op-
posite that for lag time. It remained almost unchanged in strains
pIL253 and BCD, while, in contrast, it was close to ADP-induced
maximumaggregation in strains expressingClfA, FnbpA, or SdrE.
L. lactis-induced platelet aggregation was inhibited (no aggrega-
tionwithin 40min) by both aspirin (50g/ml) and abciximab (10
g/ml), suggesting that this was true platelet aggregation (data not
shown).
The results for platelet aggregation by L. lactis under high-
shear conditions are depicted in Fig. 2. As observed by the ag-
gregometry method, the L. lactis ClfA, FnbpA, and SdrE strains
induced aggregation within significantly shorter times (1, 1, and 3
min, respectively) than the L. lactis BCD strain or L. lactis pIL253
(	5 min) (P 0.05) and presented significantly higher percent-
ages of aggregation. No platelet aggregation was observed on non-
bacterium-covered chambers (control).
In vivo studies. Bolus inoculation of 106 CFU of L. lactis was
followed by bacteremia of 5 103 to 9 103 CFU/ml 1 min after
inoculation. In comparison, bacteremia levels during continuous
infusion had median values of 10 CFU (range, 1 to 24 CFU/ml),
which were similar in all the L. lactis groups. Thus, the level of
FIG 1 L. lactis-induced platelet aggregation measured by light transmission
aggregometry. Results are expressed as means standard deviations for three
independent assays. (A) Lag time (i.e., the time from the addition of bacteria to
the platelets to the first signs of aggregation). Lag times of 10 min indicate that
there was no aggregation even when the time was extended to 40 min. (B)
Maximal aggregation (i.e., the maximum extent of aggregation over 40 min).
Asterisks indicate a significant difference (P  0.05) from the results for L.
lactis pIL253 (by an unpaired t test).
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bacteremia was 375 to 5,000 times greater after bolus administra-
tion than during continuous inoculation.
Figure 3 depicts the contributions of ClfA, FnbpA, BCD, and
SdrE expressed in L. lactis to the initiation of IE. Descriptive anal-
ysis showed that the percentages of infection for the ClfA and
FnbpA groups were significantly higher than for the L. lactis
pIL253 control group. Both platelet aggregation (PlAgg), ob-
served with L. lactis SdrE, and PlAgg plus fibrinogen adherence
(Fg), observed with L. lactisClfA, favored the occurrence of endo-
carditis, although there were not enough data for the SdrE group
to generate a significant result by Fisher’s exact test, which remains
rather conservative. The data also suggest that fibronectin adher-
ence (Fn) may further promote infection when it occurs in asso-
ciation with fibrinogen adherence and platelet aggregation, as in
the L. lactis FnbpA strain, but not when it is present alone, as in the
L. lactis BCD strain. Again, however, comparison of the FnbpA
and ClfA strains by Fisher’s test failed to detect any significant
difference (P	 0.281). It is remarkable that the patterns of infec-
tion in the bolus and continuous infusion models appear similar,
although the levels of circulating bacteria in the continuous infu-
sion model are much lower.
The logistic regression model for the probability of infection
was used in subsequent statistical analysis. Because for each strain
no significant differences could be observed between the two in-
oculation methods (P, 	0.525 by Fisher’s exact test), data were
pooled. This model did reveal that the interaction term (Fg 
PlAgg) Fn was not significant, either with separate data or with
pooled data (P 	 0.449); hence, it was dropped from the model.
All interactions involving the bolus termwere also dropped. Table
1 presents parameter estimates and odds ratios (OR) for a reduced
model that includes only the additive effects of PlAgg, FnPlAgg,
and Fn, as well as an average bolus effect. Recall that parameters in
a logistic regressionmodel are to be interpreted as the logarithmof
the OR [log(OR)] comparing a group of interest with a control
group (which in our context refers to animals inoculated with L.
lactis pIL253 using continuous inoculation). The reduced model
(Table 1) confirms that the bolus injection and continuous-infusion
models exhibit essentially the same infection pattern, as suggested by
the nonsignificant bolus term. On the other hand, PlAgg alone or in
association with Fg increases the OR of infection to 4.03 (P
 0.045)
or 11.94 (P 0.001), respectively. Note that we gain statistical power
in themodeling, which translates into a significant effect of PlAgg on
the risk of infection (P
 0.045), while this was not detected by Fish-
er’s test comparing the odds of infection in the L. lactis SdrE and L.
lactispIL253groups.Finally, Fnappears relativelyneutral (P
0.414)
with respect to the risk of infection.
Production of cytokines. Concentrations of TNF, IL-1, IL-
1-, IL-6, and IL-10 in plasmawere quantified by Luminex 2 h and
6 h after bolus and continuous-infusion inoculation of rats with L.
FIG 2 Ability of L. lactis to trigger platelet aggregation under high-shear conditions (rate, 800 s1), determined by using -Slide VI0.4 flow chambers. Images
were taken 3 min after platelet perfusion over immobilized bacteria (i.e., the longest lag time for aggregating strains) and are representative fields for 3
independent experiments that yielded similar results. The percentage of chamber surface coverage (platelet aggregation) is given next to each image. For the
control, a suspension of PRP was perfused over a chamber without adherent bacteria. Asterisks indicate a significant difference (P 0.001) from the result for
pIL253 (by an unpaired t test).
FIG 3 Experimental endocarditis induced by bolus or continuous-infusion
inoculation. Rats with catheter-induced aortic vegetations were challenged
either with an i.v. bolus (1 ml in 1 min) of 106 CFU or with the same total
absolute numbers of L. lactis delivered as a continuous infusion of 0.0017
ml/min over 10 h. Bars indicate the percentages of infected vegetations for each
inoculation method. The recombinant strains of L. lactis are given under the
bars, and the factors expressed by these strains are given above the bars. Fg,
fibrinogen binding; Fn, fibronectin binding; PlAgg, platelet aggregation. *,P
0.05; **, P 0.01; ***, P 0.001; n.s., not significant (by Fisher’s exact test).
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lactis pIL253, L. lactis expressing ClfA, and L. lactis expressing
FnbpA. Cytokines were produced at different levels depending on
the experimental conditions. TNF, IL-1, and IL-6were produced
at low levels, and IL-1 at high levels (up to the ng/ml range), in
rats infected with the L. lactis ClfA and FnbpA strains (Fig. 4).
Some interesting trends were observed, although intergroup
differences in cytokine concentrations were most often not statis-
tically significant because of interindividual variability and the
relatively small number of animals tested (3 in each group). The
production of TNF, IL-1, IL-1-, IL-6, and IL-10 (Fig. 4; also
data not shown) peaked earlier following bolus inoculation (2 h)
than following continuous-infusion inoculation (6 h) of the L.
lactis ClfA and FnbpA strains. This likely results from a high but
transient presence of bacteria in the blood following bolus injec-
tion, compared with the low but constant level of bacteria in the
blood after continuous inoculation.
Following continuous inoculation, TNF and IL-1 were close
to basal levels or undetectable in all groups for the whole period
studied. IL-1 and IL-6 levels, which were close to basal levels in
all groups at 2 h, strongly increased at 6 h in rats infected with L.
lactis expressing FnbpA (795.4  573.2 and 106.5  8.7 pg/ml,
respectively) and were higher than those in rats infected with L.
lactis pIL253 (162.5  9.16 and 41.2  29.4 pg/ml) or L. lactis
expressing ClfA (223.1  10.8 and 56.6  1.6 pg/ml). Plasma
IL-10 levels did not differ among the L. lactis groups at either 2 h
(360 to 461 pg/ml) or 6 h (441 to 638 pg/ml), indicating that the
ability to induce IL-10 secretionwas independent of the adherence
properties of L. lactis in this model (data not shown).
DISCUSSION
The ability to bind fibrinogen and/or fibronectin, and to trigger
platelet aggregation, has been shown to be amajor determinant in
the pathogenesis of S. aureus IE. This was demonstrated in exper-
imental endocarditis models using S. aureus protein-defective
mutants or, more convincingly, employing L. lactis recombinants
individually expressing the fibrinogen-binding protein ClfA or
the fibronectin-binding protein FnbpA (12, 13, 32, 33). In these
studies, experimental IE was induced in animals by artificial bolus
inoculation of high bacterial numbers, leading to transient high-
grade bacteremia. However, S. aureus IE in humans may possibly
result from recurrent low-grade bacteremia rather than from
transient high-grade bacteremia (22, 23).
In the present study, we used a newly developed rat model of
experimental IE by low-grade bacteremia, resembling human
low-grade bacteremia, to explore further the individual contribu-
tions of fibrinogen binding, fibronectin binding, and platelet ag-
TABLE 1 Coefficients, odds ratios, and P values for the logistic regression modela
Parameter
Bolus inoculation Continuous infusion Pooled data
Log(OR) OR P Log(OR) OR P
No. of infected
vegetations/total Log(OR) OR P
Control (intercept)b 1.69 0.19 0.014 2.45 0.09 0.001 2.22 0.11 0.001
Bolus 0.30 1.35 0.459
PlAgg 1.18 3.24 0.241 1.61 4.98 0.099 6/18 1.39 4.03 0.045
Fg PlAgg 2.37 10.6 0.001 2.63 13.8 0.001 23/40 2.48 11.9 0.001
Fn 0.03 1.03 0.964 0.72 2.05 0.269 2/18 0.37 1.45 0.414
a An OR larger than 1 indicates a higher risk (odds) of infection, while an OR smaller than 1 indicates a lower risk of infection, in the group of interest than in the control group. A
significant result refers to a log(OR) significantly different from zero, or an OR significantly different from 1. P values of0.05 are shown in boldface.
b The intercept refers to the logarithm of the odds in the control group (L. lactis pIL253). Values for the intercept are expressed as log(odds) and odds.
FIG 4 Levels of TNF, IL-1, IL-1, and IL-6 in the plasma of rats 2 h and 6 h
after the initiation of inoculationwith L. lactis pIL253, L. lactis expressingClfA,
or L. lactis expressing FnbpA by either bolus (left) or low-grade continuous
infusion (right). Horizontal dashed lines represent background values at 0 h.
Results are expressed asmeans standard errors of themeans for three values
per group. Asterisks indicate a significant difference (P 0.05) from cytokine
production in L. lactis pIL253 as determined by ANOVA with Tukey’s multi-
ple-comparison test.
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gregation to the initiation of S. aureus IE in a more realistic situa-
tion. A panel of recombinant L. lactis strains expressing individual
S. aureus cell wall proteins, to circumvent their redundancy of
function, was used.
Several interesting observations can be made. First, the inci-
dence of experimental IE (expressed as a percentage) by low-grade
bacteremia was similar to that resulting from bolus inoculation,
supporting the use of this new model for the study of pathogenic
factors. Second, these results strengthen earlier observations on
the essential role of adherence to fibrinogen in the initiation of IE
and confirm that the interaction with fibronectin alone is not suf-
ficient to induce the disease. This is supported by an increased rate
of infection by L. lactis expressing either ClfA or FnbpA and the
absence of valve infection by L. lactis expressing BCD, the trun-
cated form of FnbpA lacking fibrinogen-binding activity. A limi-
tation of our study using recombinant L. lactis expressing S. au-
reus-derived factors is that it is not always feasible to generate
strains with specific combinations of factors. For instance, it is not
possible to induce fibrinogen adherence without also inducing
platelet aggregation. As a consequence, a full factorial design is
impossible to set up, and some confounding remains within the
main effects. Despite this limitation, platelet aggregation, alone or
in combination with fibrinogen adherence, was shown to increase
the risk of infection significantly, since a higher rate of IE was
observed with L. lactis expressing SdrE or ClfA, respectively.
In vitro results also suggest that fibrinogen is themainmediator
of S. aureus platelet aggregation. Indeed, the L. lactis ClfA and
FnbpA strains, both binding to fibrinogen, triggered platelet ag-
gregation, while the L. lactis BCD strain, expressing the fibrino-
gen-truncated form of FnbpA, did not. The absence of in vitro
platelet aggregation by L. lactis expressing BCD is in apparent
contradiction of previous findings by Fitzgerald et al. (5), where
BCD, expressed in L. lactis NZ9800, supported platelet aggrega-
tion (5). The reasons for this discrepancy remain unknown. It is
possible that BCD is expressed in L. lactis pIL253 at a lower level
than in L. lactisNZ9800. This could, in turn, result in a longer time
to platelet aggregation, since this process requires a minimum
level of protein expressed on the surfaces of the cells (7). Heying et
al. (34) have also observed that L. lactis expressing BCD binds
significantly less fibronectin than L. lactis expressing FnbpA, thus
likely contributing to decreased interaction with platelets.
Although binding to fibronectin is not a prerequisite for valve
infection, the ability to adhere to fibronectin in addition to attach-
ing to fibrinogen (i.e., by FnbpA) contributed further to infection
and to disease severity, as suggested both by a slighter increase in
the rate of valve infection and by an elevated systemic inflamma-
tory response. Indeed, although we analyzed only a small number
of animals, which can limit the evaluation of the results, it is in-
teresting the high levels of the proinflammatory cytokines IL-1
and IL-6 in plasma following both bolus and continuous-infusion
inoculation with L. lactis expressing FnbpA, although bolus inoc-
ulation increased cytokine levels earlier than did continuous in-
oculation. FnbpA was previously shown to induce the production
of IL-6 by endothelial cells in vitro (19, 35) and to be amajor player
responsible for both the proinflammatory and the procoagulant
endothelium responses in vivo during S. aureus endovascular in-
fections (15, 18, 36). The increase in the level of IL-1 is in line
with the findings of previous studies showing that fibronectin in-
duces IL-1 gene transcription and increases IL-1 protein secre-
tion in vitro (37). FnbpA was shown to trigger the uptake of L.
lactis (and S. aureus) by endothelial cells (16, 18, 38). Collectively,
these results compared well with the elevated levels of IL-1 and
IL-6 observed after internalization of S. aureus by endothelial cells
in vitro (20) and in patients with S. aureus IE (39–41). Previous
studies by Dankert el al. indicated that IL-1 production could
favor Streptococcus mitis IE in rabbits, in amodel of IE induced by
injection of a large bacterial inoculum (42). The results of the
present study support the possibility that an enhanced inflamma-
tory response may indeed promote the development of IE, as ob-
served after inoculation with the L. lactis FnbpA strain.
In conclusion, the present study demonstrates that IE is equally
inducible by either low-grade or bolus bacteremia. The low-grade
model appears to be a reliable system for realistic assessment of the
roles of bacterial pathogenic factors in IE and strengthens the crit-
ical role of ClfA and platelet aggregation in IE initiation. These
data may have implications for the design of appropriate preven-
tion strategies for S. aureus IE in a context closer to the human
situation. Antibiotics are unlikely to solve the problem of IE pro-
phylaxis for humans in a setting of recurrent low-level bacteremia.
Thus, other approaches should be explored. Active and passive
immunization against ClfA has already been attempted in humans
based on some protection obtained against S. aureus infections in
different animal models (43–45). However, no single vaccine was
effective in clinical trials (46). Antiplatelet intervention using a
combination of aspirin and ticlopidine to prevent experimental S.
aureus endocarditis in rabbits was tested previously (47), but this
strategy was not totally successful. The major drawback of this
study could be the use of the classical high-inoculum infection
model of IE. It is likely that the antiplatelet prophylaxis was over-
whelmed by the high-grade bacteremia. Due to the important role
of platelets in IE initiation anddevelopment, the use of antiplatelet
drugs warrants further examination in the context of a low-grade
bacteremia model of IE. This approach, if effective, could lead to
the development of global IE prevention strategies, since both
staphylococci and streptococci, the most frequent IE pathogens,
induce this infection through interaction with platelets.
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